Final published version
Research output: Contribution to Journal/Magazine › Literature review › peer-review
<mark>Journal publication date</mark> | 04/2015 |
---|---|
<mark>Journal</mark> | BJOG: An International Journal of Obstetrics and Gynaecology |
Issue number | 5 |
Volume | 122 |
Number of pages | 8 |
Pages (from-to) | 615-622 |
Publication Status | Published |
Early online date | 5/01/15 |
<mark>Original language</mark> | English |
Background
Patient-reported outcome measures (PROMs) are used to assess the impact of health care on a patient's health. Within the gynaecological oncology setting, multiple PROMs have been adopted but no assessment has been made in terms of their psychometric qualities and robustness.
Objectives
To undertake a systematic review to identify the most psychometrically robust and appropriate PROM used in the gynaecological oncology setting.
Search strategy
A search of the bibliographic database of the Oxford PROM group, plus nine additional databases, was carried out along with citation-tracking and hand searches.
Selection criteria
Studies examining the psychometric properties of outcome measures tested in gynaecological cancer populations were selected by three blinded reviewers.
Data collection and analysis
Studies were independently assessed and data extracted. Analysis included an appraisal of the psychometric properties and functionality of the included PROMs to guide recommendations.
Main results
Eighteen PROMs tested in gynaecological oncology settings were identified. These were categorised into seven areas of focus, and the most psychometrically robust tools were identified: (1) generic (no recommendation); (2) general cancer (EORTC QLQ-C30 and FACT-G); (3) pelvic cancer (QUESTGY); (4) ovarian cancer (EORTC QLQ-OV28); (5) cervical cancer (EORTC QLQ-CX24); (6) endometrial cancer (EORTC QLQ-EN 24); and (7) vulval cancer (FACT-V).
Author's conclusions
Seven PROMs were recommended for use in six gynaecological populations. No single tool was identified that had been tested in all disease groups. Some showed promise, but a lack of conceptual clarity about the core outcomes and the rationale for use will require further testing using well-constructed studies.